CNTX
Context Therapeutics Inc.
Biotechnology
Market Cap$214M
5Y Perf.-59.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
CNTX vs AGIO vs IMVT vs CRL
Revenue, margins, valuation, and 5-year total return — side by side.
AGIO
Agios Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.64B
5Y Perf.-41.4%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+238.6%
CRL
Charles River Laboratories International, Inc.
Medical - Diagnostics & Research
Market Cap$8.98B
5Y Perf.-59.4%
CNTX vs AGIO vs IMVT vs CRL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CNTX | AGIO | IMVT | CRL |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $214M | $1.64B | $5.53B | $8.98B |
| Revenue (TTM) | $0.00 | $66M | $0.00 | $4.03B |
| Net Income (TTM) | $-40M | $-423M | $-464M | $-185M |
| Gross Margin | — | 82.1% | — | 24.9% |
| Operating Margin | — | -7.2% | — | 11.8% |
| Forward P/E | — | — | — | 16.4x |
| Total Debt | $112K | $62M | $98K | $3.07B |
| Cash & Equiv. | $66M | $89M | $714M | $214M |
CNTX vs AGIO vs IMVT vs CRL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CNTX
AGIO
IMVT
CRL
| Stock | Oct 21 | May 26 | Return |
|---|---|---|---|
| Context Therapeutic… (CNTX) | 100 | 40.5 | -59.5% |
| Agios Pharmaceutica… (AGIO) | 100 | 58.6 | -41.4% |
| Immunovant, Inc. (IMVT) | 100 | 338.6 | +238.6% |
| Charles River Labor… (CRL) | 100 | 40.6 | -59.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CNTX vs AGIO vs IMVT vs CRL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CNTX leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Agios Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion. CRL also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
CNTX
Context Therapeutics Inc.
The Income Pick
CNTX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.46
- Lower volatility, beta 0.46, Low D/E 0.2%, current ratio 8.52x
- 4.9% margin vs AGIO's -6.4%
- Beta 0.46 vs CRL's 1.52, lower leverage
Best for: income & stability and sleep-well-at-night
AGIO
Agios Pharmaceuticals, Inc.
The Growth Play
AGIO is the #2 pick in this set and the best alternative if growth exposure and defensive is your priority.
- Rev growth 48.0%, EPS growth -161.2%, 3Y rev CAGR 56.0%
- Beta 1.12, current ratio 11.46x
- 48.0% revenue growth vs CNTX's -45.5%
Best for: growth exposure and defensive
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 173.6% 10Y total return vs CRL's 119.2%
Best for: long-term compounding
CRL
Charles River Laboratories International, Inc.
The Niche Pick
CRL is the clearest fit if your priority is efficiency.
- -2.5% ROA vs CNTX's -54.8%
Best for: efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AGIO | 48.0% revenue growth vs CNTX's -45.5% |
| Quality / Margins | CNTX | 4.9% margin vs AGIO's -6.4% |
| Stability / Safety | CNTX | Beta 0.46 vs CRL's 1.52, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | CNTX | +201.4% vs AGIO's -2.4% |
| Efficiency (ROA) | CRL | -2.5% ROA vs CNTX's -54.8% |
CNTX vs AGIO vs IMVT vs CRL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
Segment breakdown not available.
FY 2025
CNTX vs AGIO vs IMVT vs CRL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCRLLAGGINGIMVT
Who Leads Where
CRL leads in 3 of 6 categories
CNTX leads 1 • AGIO leads 0 • IMVT leads 0 • 1 tied
Explore the data ↓IMVTImmunovant, Inc.
0leads
AGIOAgios Pharmaceuticals…
0leads
CNTXContext Therapeutics …
1leads
CRLCharles River Laborat…
3leads
6 Total Categories
CATEGORYLEADERvs CNTXvs AGIOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CRL3/6
Valuation MetricsMultiples, price ratios, and targets
CRL2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CRL5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
CNTX4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CRL leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CRL and IMVT operate at a comparable scale, with $4.0B and $0 in trailing revenue. Profitability is closely matched — net margins range from -4.6% (CRL) to -6.4% (AGIO). On growth, AGIO holds the edge at +137.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CNTXContext Therapeut… | AGIOAgios Pharmaceuti… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $66M | $0 | $4.0B |
| EBITDAEarnings before interest/tax | -$43M | -$470M | -$487M | $757M |
| Net IncomeAfter-tax profit | -$40M | -$423M | -$464M | -$185M |
| Free Cash FlowCash after capex | -$21M | -$385M | -$423M | $391M |
| Gross MarginGross profit ÷ Revenue | — | +82.1% | — | +24.9% |
| Operating MarginEBIT ÷ Revenue | — | -7.2% | — | +11.8% |
| Net MarginNet income ÷ Revenue | — | -6.4% | — | -4.6% |
| FCF MarginFCF ÷ Revenue | — | -5.8% | — | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +137.7% | — | +1.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -80.0% | -9.0% | +19.7% | -160.0% |
CRL leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
CRL leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | CNTXContext Therapeut… | AGIOAgios Pharmaceuti… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| Market CapShares × price | $214M | $1.6B | $5.5B | $9.0B |
| Enterprise ValueMkt cap + debt − cash | $148M | $1.6B | $4.8B | $11.8B |
| Trailing P/EPrice ÷ TTM EPS | -6.13x | -3.87x | -9.97x | -62.52x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 16.42x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 12.98x |
| Price / SalesMarket cap ÷ Revenue | — | 30.30x | — | 2.24x |
| Price / BookPrice ÷ Book value/share | 3.67x | 1.34x | 5.83x | 2.81x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 17.31x |
CRL leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
CRL leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
CRL delivers a -5.7% return on equity — every $100 of shareholder capital generates $-6 in annual profit, vs $-60 for CNTX. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRL's 0.95x. On the Piotroski fundamental quality scale (0–9), CRL scores 4/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | CNTXContext Therapeut… | AGIOAgios Pharmaceuti… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -60.0% | -34.1% | -47.1% | -5.7% |
| ROA (TTM)Return on assets | -54.8% | -31.7% | -44.1% | -2.5% |
| ROICReturn on invested capital | — | -26.3% | — | +6.3% |
| ROCEReturn on capital employed | -50.9% | -33.8% | -66.1% | +8.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.00x | 0.05x | 0.00x | 0.95x |
| Net DebtTotal debt minus cash | -$66M | -$27M | -$714M | $2.9B |
| Cash & Equiv.Liquid assets | $66M | $89M | $714M | $214M |
| Total DebtShort + long-term debt | $112,064 | $62M | $98,000 | $3.1B |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | 6.38x |
CRL leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
CNTX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $4,569 for CNTX. Over the past 12 months, CNTX leads with a +201.4% total return vs AGIO's -2.4%. The 3-year compound annual growth rate (CAGR) favors CNTX at 56.7% vs CRL's -1.4% — a key indicator of consistent wealth creation.
| Metric | CNTXContext Therapeut… | AGIOAgios Pharmaceuti… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +50.3% | +1.3% | +5.1% | -10.1% |
| 1-Year ReturnPast 12 months | +201.4% | -2.4% | +96.1% | +32.8% |
| 3-Year ReturnCumulative with dividends | +285.1% | +8.3% | +40.9% | -4.2% |
| 5-Year ReturnCumulative with dividends | -54.3% | -50.7% | +62.4% | -46.9% |
| 10-Year ReturnCumulative with dividends | -54.3% | -42.2% | +173.6% | +119.2% |
| CAGR (3Y)Annualised 3-year return | +56.7% | +2.7% | +12.1% | -1.4% |
CNTX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CNTX and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
CNTX is the less volatile stock with a 0.46 beta — it tends to amplify market swings less than CRL's 1.52 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs AGIO's 59.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CNTXContext Therapeut… | AGIOAgios Pharmaceuti… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.46x | 1.12x | 1.37x | 1.52x |
| 52-Week HighHighest price in past year | $3.62 | $46.00 | $30.09 | $228.88 |
| 52-Week LowLowest price in past year | $0.49 | $22.24 | $13.36 | $131.30 |
| % of 52W HighCurrent price vs 52-week peak | +64.4% | +59.8% | +90.5% | +79.5% |
| RSI (14)Momentum oscillator 0–100 | 48.4 | 41.9 | 60.2 | 57.2 |
| Avg Volume (50D)Average daily shares traded | 901K | 1.0M | 1.4M | 806K |
Evenly matched — CNTX and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CNTX as "Buy", AGIO as "Buy", IMVT as "Buy", CRL as "Buy". Consensus price targets imply 125.3% upside for CNTX (target: $5) vs 12.9% for CRL (target: $205).
| Metric | CNTXContext Therapeut… | AGIOAgios Pharmaceuti… | IMVTImmunovant, Inc. | CRLCharles River Lab… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $5.25 | $37.75 | $45.50 | $205.43 |
| # AnalystsCovering analysts | 6 | 29 | 23 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +4.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CRL leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). CNTX leads in 1 (Total Returns). 1 tied.
Best OverallCharles River Laboratories … (CRL)Leads 3 of 6 categories
Loading custom metrics...
CNTX vs AGIO vs IMVT vs CRL: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is CNTX or AGIO or IMVT or CRL a better buy right now?
For growth investors, Agios Pharmaceuticals, Inc.
(AGIO) is the stronger pick with 48. 0% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Analysts rate Context Therapeutics Inc. (CNTX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CNTX or AGIO or IMVT or CRL?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to -54. 3% for Context Therapeutics Inc. (CNTX). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus CNTX's -54. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CNTX or AGIO or IMVT or CRL?
By beta (market sensitivity over 5 years), Context Therapeutics Inc.
(CNTX) is the lower-risk stock at 0. 46β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately 230% more volatile than CNTX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CNTX or AGIO or IMVT or CRL?
By revenue growth (latest reported year), Agios Pharmaceuticals, Inc.
(AGIO) is pulling ahead at 48. 0% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Context Therapeutics Inc. grew EPS 17. 4% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, AGIO leads at 56. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CNTX or AGIO or IMVT or CRL?
Context Therapeutics Inc.
(CNTX) is the more profitable company, earning 0. 0% net margin versus -764. 0% for Agios Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRL leads at 12. 6% versus -873. 9% for AGIO. At the gross margin level — before operating expenses — AGIO leads at 78. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CNTX or AGIO or IMVT or CRL more undervalued right now?
Analyst consensus price targets imply the most upside for CNTX: 125.
3% to $5. 25.
07Which pays a better dividend — CNTX or AGIO or IMVT or CRL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CNTX or AGIO or IMVT or CRL better for a retirement portfolio?
For long-horizon retirement investors, Context Therapeutics Inc.
(CNTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 46)). Charles River Laboratories International, Inc. (CRL) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CNTX: -54. 3%, CRL: +119. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CNTX and AGIO and IMVT and CRL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CNTX is a small-cap quality compounder stock; AGIO is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; CRL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.